Enjoy complimentary customisation on priority with our Enterprise License!
The predictive presymptomatic testing market size is forecast to increase by USD 2.59 billion, at a CAGR of 10.03% between 2023 and 2028. The global Predictive Presymptomatic Testing market is experiencing significant growth due to several key factors. Firstly, the increasing healthcare spending worldwide is driving demand for advanced diagnostic tools and genetic testing. Secondly, the rise in awareness toward early screening of genetic disorders has led to an increasing demand for predictive presymptomatic testing. This testing allows individuals with a family history of certain genetic disorders to identify their risk and take preventative measures before symptoms appear. Genetic counseling plays a crucial role in this process, providing essential information and support to individuals and families. As a result, the market for predictive presymptomatic testing is expected to grow steadily in the coming years.
For More Highlights About this Report, Request Free Sample
In the realm of wearable technology, wrist watches and jewelry have evolved beyond mere accessories into functional devices that monitor health risks and track sleep patterns. Innovations like augmented reality and virtual reality are reshaping how we interact with information and environments, enhancing experiences through speech recognition and immersive visuals. Devices such as Google Glass integrate seamlessly into daily life, offering real-time data and enhancing safety with features like camera integration for recording events. For active lifestyles, wearables like heart rate monitors and shoes equipped with sensors provide insights into exercise intensity and performance. The development of coexistence testing ensures these technologies work harmoniously without interference, akin to how pigeons navigate without colliding in crowded skies. From tracking steps to enhancing productivity, wearable technology continues to blur the lines between fashion and functionality, promising a future where innovation meets everyday convenience.
The increasing healthcare spending worldwide is one of the key drivers supporting the predictive presymptomatic testing market growth. The governments of developed nations such as the US, Germany, and others have increased their healthcare expenditure in recent years. Through the support of the governments and a surge in healthcare expenditures, global private and public healthcare facilities and not-for-profit organizations (NPOs) are able to provide their services to patients. According to The World Health Organization (WHO), global spending on healthcare continually rose between 2000 and 2018 and reached USD 8.3 trillion or 10% of global GDP. Thus, the increasing expenditure in the global healthcare sector and the increase in government aid to healthcare providers will boost the growth of the global predictive presymptomatic testing market during the forecast period.
Significant Market Trends
The growing prevalence of genetic diseases is one of the key predictive presymptomatic testing market trends that is contributing to the market growth. According to the Centers for Disease Control and Prevention (CDC), in the US, more than 1.6 million patients are getting diagnosed with cancer every year, with almost 600,000 fatalities. The incidence of genetic disorders is gradually increasing. Moreover, the increasing incidence of chronic diseases and genetic disorders leads researchers and scientists to opt for predictive presymptomatic testing for diagnosing and treating patients. Researchers are increasingly focusing on predictive presymptomatic testing due to its high impact on diagnosing and treating diseases using gene therapy and recombinant vaccines. Hence, an increase in the prevalence of genetic disorders is expected to drive the growth of the global predictive presymptomatic testing market during the forecast period.
Major Market Challenge
The high cost of tests is one of the factors hindering the predictive presymptomatic testing market growth. For instance, in 2019, the per capita healthcare expenditure was USD 7,138 in Switzerland, USD 6,748 in Norway, and USD 6,731 in Germany. Additionally, in developing countries such as India, China, and others, due to a lack of resources and low per capita income, patients are unable to avail themselves of predictive presymptomatic test kits. The absence of proper healthcare infrastructure and less amount of government aid received in the form of medical expense reimbursement further acts as a challenge for the patients in these countries. Thus, the global per capita healthcare cost is expected to increase during the forecast period. This will negatively affect the growth of the global predictive presymptomatic testing market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
23andMe Holding Co. - The company offers predictive presymptomatic testing such as BRCA1 and BRCA2 which helps in repairing DNA breaks that can lead to cancer.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The cancer diseases segments is estimated to witness significant growth during the forecast period. Cancer is usually not considered a genetic disorder. However, certain types of cancers, such as breast, ovarian, prostate, and colorectal cancer, are strongly influenced by genes. These types of cancers are passed on to the next generation. Thus, predictive and presymptomatic testing is used for the diagnosis of hereditary-based cancers such as breast and ovarian cancer.
Get a glance at the market share of various regions Download the PDF Sample
The cancer diseases segments accounted for USD 1.40 billion in 2018 and showed a gradual increase during the forecast period. Healthy female mutation carriers of BReast CAncer (BRCA) genes have a high risk of acquiring breast cancer and ovarian cancer. However, BRCA genes are not the only genes that are associated with breast and ovarian cancer. Various research studies have identified approximately more than 100 new gene variants which can be associated with an increased risk of cancer, such as breast, ovarian, and prostate cancer. These new gene variants only slightly increase the risk of cancer individually. However, a combination of these genes can increase the overall risk of developing cancer.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. North America accounts for the largest revenue share of the global predictive presymptomatic testing market. The US and Canada account for the highest market shares in the region. The presence of many vendors that offer predictive presymptomatic test kits in the US is a significant factor that drives the growth of the regional market. Furthermore, the high healthcare spending in the US and Canada and the presence of well-established healthcare infrastructure are also fueling the growth of the regional market to a great extent. The increasing prevalence of multiple types of cancer is driving the predictive presymptomatic testing market in the US. In the US, the prevalence of cancer has been increasing in recent years.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion " for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
You may also interested in below market reports:
1. Predictive Analytics Market Analysis North America, Europe, APAC, South America, Middle East and Africa - US, China, Japan, Germany, UK - Size and Forecast
2. Predictive Maintenance (PdM) Market Analysis North America, Europe, APAC, South America, Middle East and Africa - US, Canada, China, UK, Germany - Size and Forecast
3. Industrial Predictive Maintenance Market in APAC in APAC by End-user, Deployment, and Geography - Forecast and Analysis
The integration of wearable technology continues to expand from devices worn on the neck like lanyards and necklaces, to those on the head, such as smart glasses and headphones. Innovations extend to shoes with embedded sensors for tracking fitness metrics, and bags equipped with charging ports for smartphones. This evolution enhances human-computer interaction by seamlessly integrating technology into everyday clothing and accessories like watches and eyeglasses, minimizing concerns over weight and bulkiness. Safety measures against fire hazards and heat are paramount, influencing the design of devices like calculator watches, portable radios, and body cameras used in military and policing applications. GPS technology aids in navigation for personal tasks and managing daily workloads, while augmented memory technology enhances VR and AR experiences. Sound shirts and vibrating bracelets cater to individuals needing portable translators for enhanced independence. Cameras in wearables ensure comprehensive security and efficient data capture in diverse settings.
Market Scope |
|
Report Coverage |
Details |
Page number |
136 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.03% |
Market growth 2024-2028 |
USD 2.59 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
8.88 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 42% |
Key countries |
US, Germany, Japan, UK, and France |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
23andMe Holding Co., Abbott Laboratories, Amgen Inc., BioAxis DNA Research Centre P Ltd., Color Health Inc., Deep Genomics Inc., Direct Laboratory Services LLC, DNA and U, Editas Medicine Inc., Healius Ltd., Illumina Inc., International Business Machines Corp., Mapmygenome India Ltd., myDNA Life Ltd., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Quest Diagnostics Inc., Sysmex Corp., and Veritas Genetics Inc. |
Market dynamics |
Parent market analysis, Market forecasting growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.